Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

M Agrawal, S Saraf, S Saraf, SG Antimisiaris… - Journal of controlled …, 2018 - Elsevier
Abstract According to the Alzheimer Association Report (2017), Alzheimer's disease (AD) is
the 6th primary cause of death in the USA, which affects nearly 5.5 million people. In the …

Proteostasis of islet amyloid polypeptide: a molecular perspective of risk factors and protective strategies for type II diabetes

D Milardi, E Gazit, SE Radford, Y Xu… - Chemical …, 2021 - ACS Publications
The possible link between hIAPP accumulation and β-cell death in diabetic patients has
inspired numerous studies focusing on amyloid structures and aggregation pathways of this …

Iron and Alzheimer's disease: from pathogenesis to therapeutic implications

JL Liu, YG Fan, ZS Yang, ZY Wang… - Frontiers in neuroscience, 2018 - frontiersin.org
As people age, iron deposits in different areas of the brain may impair normal cognitive
function and behavior. Abnormal iron metabolism generates hydroxyl radicals through the …

Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems

JM Lü, PH Lin, Q Yao, C Chen - Journal of cellular and …, 2010 - Wiley Online Library
Introduction• Free radical scavenging‐Scavenging superoxide and other ROS‐Scavenging
hydroxyl radical and other ROS‐Stable radical scavenging• Metal ion (Fe2+, Fe3+, Cu2+ …

Nanoparticles in cellular drug delivery

AH Faraji, P Wipf - Bioorganic & medicinal chemistry, 2009 - Elsevier
This review highlights the properties of nanoparticles used in targeted drug delivery,
including delivery to cells as well as organelle targets, some of the known pharmacokinetic …

The metallobiology of Alzheimer's disease

AI Bush - Trends in neurosciences, 2003 - cell.com
The cause of Alzheimer's disease (AD) is closely related to the aggregation of a normal
protein, β-amyloid (Aβ), within the neocortex. Recently, evidence has been gathered to …

Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease

G Bartzokis - Neurobiology of aging, 2004 - Elsevier
A hypothetical model of Alzheimer's disease (AD) as a uniquely human brain disorder
rooted in its exceptional process of myelination is presented. Cortical regions with the most …

Recent advancement in therapeutic strategies for Alzheimer's disease: Insights from clinical trials

T Khan, R Waseem, M Shahid, J Ansari… - Ageing Research …, 2023 - Elsevier
Alzheimer's disease (AD) is the most prevalent form of dementia, characterized by the
presence of plaques of amyloid beta and Tau proteins. There is currently no permanent cure …

Therapeutic potential and main methods of obtaining selenium nanoparticles

EG Varlamova, EA Turovsky, EV Blinova - International journal of …, 2021 - mdpi.com
This review presents the latest data on the importance of selenium nanoparticles in human
health, their use in medicine, and the main known methods of their production by various …

[HTML][HTML] The redox chemistry of the Alzheimer's disease amyloid β peptide

DG Smith, R Cappai, KJ Barnham - Biochimica et Biophysica Acta (BBA) …, 2007 - Elsevier
There is a growing body of evidence to support a role for oxidative stress in Alzheimer's
disease (AD), with increased levels of lipid peroxidation, DNA and protein oxidation …